Cover Image
Market Research Report
Product code 
1047590

Enteral Feed Devices-Pipeline Insight and Competitive Landscape, 2022

Published: Pre-Order | DelveInsight Business Research LLP | 60 Pages | Delivery time: 2-10 business days

Price

Back to Top
Enteral Feed Devices-Pipeline Insight and Competitive Landscape, 2022
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 60 Pages
Delivery time: 2-10 business days
  • Description
  • Table of Contents
  • List of Tables

DelveInsight's, "Enteral Feed Devices-Pipeline Insight and 2022," report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Enteral Feed Devices pipeline landscape. Due to numerous technological developments, such as programming and safety features in feeding pumps, as well as user-friendly and compact feeding pumps, the enteral feeding system market has significantly evolved. Factors such as a rise in healthcare costs; an increase in the number of preterm births; an increase in the ageing population; an increase in the prevalence of chronic diseases such as diabetes, cancer, gastrointestinal diseases and neurological disorders; an increasing understanding of enteral nutrition; and rapid developments in healthcare facilities in developing countries are expected to push the market further. This report provides a detailed study of the emerging Enteral Feed Devices along with competitive landscape to help better understand the emerging Enteral Feed Devices.

Geography Covered:

  • Global coverage

Enteral Feed Devices Overview

Enteral Feed Devices: Understanding

An enteral feeding device is a medical device used to provide nutrition to people who cannot obtain nutrition by mouth, are unable to swallow safely, or need nutritional supplementation. In addition, enteral feeding refers to intake of food via the gastrointestinal (GI) tract.

In patients suffering from chronic diseases such as malnutrition, gastrointestinal disorder, cancer, and others, enteral feeding devices are medical devices used to provide drugs and nutrition. Being fed through a tube helps them to get nutrients and keep their GI tract functioning. The whole caloric consumption of enteral feeding can be made up or can be used as a supplement. The development of compact and portable enteral feeding pumps, which are built using materials that resist cracking in high-stress applications, has also led to technological advances. Advanced pump features include suitable programming options, scheduled flushing intervals, multiple language options, and warning options for occlusion strain, previous feed rate history, and manipulation-preventing screen and programed lock-out features.

However, the use of these machines is associated with a few risks, resulting in additional healthcare costs. Most of the enteral feeding-related complications are mild, but some may be very severe.

Enteral Feed Devices Competitive Assessment

This segment of the Enteral Feed Devices report encloses its detailed analysis of various pipeline devices which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates and the latest news and press releases. The report also provides list of major players involved in the pipeline product development.

  • Product Type

Enteral Feed Devices can divided based on Types - Enteral Feeding Pumps, Enteral Feeding Tubes, Administration Sets, Enteral Syringes, and Other Consumables (Extension sets, adaptors, tapes) - are covered in this report.

  • By Age Group

Enteral Feed Devices can be divided based on the different age groups - Adult, Pediatrics.

  • By Application

Enteral Feed Devices are divided based on different applications - Gastroenterology, Neurology, Diabetes, Hyper metabolism, and others.

  • Major Players in Enteral Feed Devices

There are approx. 20+ key companies which are developing the products for Enteral Feed Devices.

  • TubeClear intervention: Actuated Medical, Inc.

In the first of three planned phases designed to evaluate the feasibility and tolerability of TubeClear to restore patency in occluded Pediatric Enteral Access Devices. Based on preliminary data obtained from this phase of the study, subsequent phases will continue to evaluate feasibility and tolerability (Phase IIA) and ultimately compare efficacy of TubeClear to the Children's Hospital of Philadelphia (CHOP) Standard Treatment to restore patency in occluded Pediatric Enteral Access Devices (EAD) (Phase IIB). The study will be completed by December 2022.

  • SmART+ System: ART Medical Ltd.

The smART+ is a comprehensive modular patient care system intended for ICU patients. The main purpose of the study is the optimization of the delivery of nutrition. The use of the smART+ Feeding tube includes a feature of facilitating correct tube placement and alerting when the tube is displaced during ongoing use. The system will automatically stop feeding if displacement is detected. If a massive reflux episode is detected by the system, a balloon located on the tube will automatically inflate and automatic GRV feature will open to prevent gastric content from regurgitating to the esophagus. The study is estimated to be completed by February 2022.

Further product details are provided in the report……..

Enteral Feed Devices Competitive Benchmarking

This segment of the reports provides analysis of the pipeline report to give a clear understanding of the comparative analysis.

The analysis is based on

  • Brand Positioning of Leading companies
  • Application
  • Industry Collaborations

Enteral Feed Devices: Commercialization Activity

This segment of the report provides a detailed list of any commercial activity in the field of Enteral Feed Devices ranging from collaboration, mergers and acquisition, recent breakthrough among others.

Development Activities

  • In June 2020, Applied Medical Technology, Inc. (AMT) announced that they have expanded G-JET product offering to include the Traditional G-JET gastric-jejunal enteral feeding tube. By expanding the G-JET portfolio to include an adjustable-length option, AMT is offering both physicians and patients a more comprehensive selection of enteral feeding devices.
  • In 2019, Fresenius Kabi completed the expansion of its plant in Aquiraz, Brazil, and increased the facility's capacity for parental nutrition production by about 30%. The company has invested ~USD 22.4 million (EUR 20 million) for this expansion.

Further commercial activities are provided in the report……..

Enteral Feed Devices: Reimbursement

  • US

Enteral nutrition (EN) is generally defined by third party payers as tube feeding for patients who cannot take food orally. EN is widely accepted in the United States as an effective, often life-sustaining therapy. Coverage and payment policies for EN differ among payers and settings. These differences often may depend on whether EN is reimbursed as a discrete therapy or subsumed into a larger benefit. In the US, the Medicare and Medicaid programs are the major public payers for EN.

Further information is provided in the report……..

Report Highlights:

  • Extensive coverage of the Enteral Feed Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Enteral Feed Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry
  • The report consists of in depth analysis of pipeline products based on various parameters

Enteral Feed Devices Report Insights

  • Enteral Feed Devices - Pipeline Analysis
  • Enteral Feed Devices - Unmet Need
  • Enteral Feed Devices - Market Dynamics
  • Enteral Feed Devices - Future Perspectives and Conclusion
  • Enteral Feed Devices - Analyst Views

Key Questions

  • What are significant companies in this segment, their information, analysis, and insights to improve R&D strategies?
  • How to identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage?
  • What are important and diverse types of Enteral Feed Devices under development?
  • What are market-entry and market expansion strategies in Enteral Feed Devices?
  • What are some of the mergers and acquisitions and to identify major players with the most promising pipeline?
  • What is in-depth analysis of the product's current stage of development, territory and estimated launch date?

Key Players

  • Fresenius Kabi AG
  • Avanos Medical, Inc.
  • Cardinal Health, Inc.
  • B. Braun Melsungen AG
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cook Medical, Inc.
  • CONMED Corporation (CONMED)
  • Nestle S.A.
  • Kimberly-Clark Corporation
  • Amsino International Inc.
  • Moog Inc.
  • C.R.Bard
  • Danone
  • ALCOR
  • Applied Medical Technologies
  • Baxter International
  • Degania Silicone Ltd.
  • Halyard Health, Inc.
  • Nestle Inc.
  • Vygon
Product Code: DIMD00012

Table of Contents

1. Key Insights

2. Enteral Feed Devices: Snapshot

3. Enteral Feed Devices

  • 3.1. Product Overview
  • 3.2. Regulatory Approvals based on Class
  • 3.3. Indications
  • 3.4. Mechanism

4. Enteral Feed Devices: Competitive Assessment

  • 4.1. Assessment by Product Type
  • 4.2. Assessment by Age Group
  • 4.3. Assessment by Application
    • 4.3.1. Gastroenterology
    • 4.3.2. Neurology
    • 4.3.3. Diabetes
    • 4.3.4. Hyper metabolism
    • 4.3.5. Others
  • 4.4. Assessment by Company
    • 4.4.1. Actuated Medical, Inc.
      • 4.4.1.1. TubeClear intervention: Actuated Medical, Inc.
      • 4.4.1.1.1. Product Information
      • 4.4.1.1.2. Research and Development
      • 4.4.1.1.3. Patent Details
      • 4.4.1.1.4. Regulatory Milestone
    • 4.4.2. ART Medical Ltd.
      • 4.4.2.1. SmART+ System: ART Medical Ltd.
      • 4.4.2.1.1. Product Information
      • 4.4.2.1.2. Research and Development
      • 4.4.2.1.3. Patent Details
      • 4.4.2.1.4. Regulatory Milestone
  • More Companies and products would be added in the final report

5. Enteral Feed Devices: Competitive Benchmarking : By Company

  • 5.1. Brand Positioning of Leading companies
  • 5.2. Analysis based on Application
  • 5.3. Analysis based on Industry Collaborations

6. Enteral Feed Devices - Commercialization Activity

  • 6.1. Collaboration
  • 6.2. Licensing
  • 6.3. Merger and Acquisition
  • 6.4. Recent Breakthroughs
  • 6.5. Literature Studies
  • 6.6. KOL Views

7. Enteral Feed Devices: Regulatory

  • 7.1. US
  • 7.2. Europe
  • 7.3. Japan

8. Enteral Feed Devices: Reimbursement

  • 8.1. Case Study - US
  • 8.2. Case Study - Europe
  • 8.3. Case Study -Japan

9. Enteral Feed Devices : Market Dynamics

  • 9.1. Unmet Needs
  • 9.2. Market Drivers
  • 9.3. Market Barriers

10. DelveInsight's Analytical Perspective

  • 10.1. PEST Analysis
  • 10.2. Future Growth Perspectives

11. Conclusion

12. Appendix

  • 12.1. Research Methodology
    • 12.1.1. Coverage
    • 12.1.2. Secondary Research

13. Bibliography

14. DelveInsight Capabilities

15. Disclaimer

16. About DelveInsight

List of Tables

  • Table 1 Total Pipeline Products
  • Table 2 Pipeline Products by Type
  • Table 3 Pipeline Products by Age Group
  • Table 4 List of Companies
  • Table 5 Actuated Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 6 TubeClear intervention - Product Status
  • Table 7 TubeClear intervention - Product Description
  • Table 8 ART Medical Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9 SmART+ System - Product Status
  • Table 10 SmART+ System - Product Description

List of Figures

  • Figure 1 List of Pipeline Products
  • Figure 2 Ongoing Clinical Trial
  • Figure 3 Ongoing Clinical Trial Pipeline Products by Type
  • Figure 4 Ongoing Clinical Trial Pipeline Products by Age Group